Publication

Therapeutic RNA Delivery for COVID and Other Diseases

Downloadable Content

Persistent URL
Last modified
  • 05/21/2025
Type of Material
Authors
    Curtis Dobrowolski, Georgia Institute of TechnologyKalina Paunovska, Georgia Institute of TechnologyMarine ZC Hatit, Georgia Institute of TechnologyMelissa P Lokugamage, Georgia Institute of TechnologyJames Dahlman, Emory University
Language
  • English
Date
  • 2021-03-04
Publisher
  • WILEY
Publication Version
Copyright Statement
  • © 2021 Wiley‐VCH GmbH
License
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 10
Issue
  • 15
Start Page
  • e2002022
End Page
  • e2002022
Grant/Funding Information
  • This work was funded by the National Institutes of Health (R01‐GM132985 and UG3‐TR002855, awarded to J.E.D.)
Abstract
  • RNA can alter the expression of endogenous genes and can be used to express therapeutic proteins. As a result, RNA-based therapies have recently mitigated disease in patients. Yet most potential RNA therapies cannot currently be developed, in large part because delivering therapeutic quantities of RNA drugs to diseased cells remains difficult. Here, recent studies focused on the biological hurdles that make in vivo drug delivery challenging are described. Then RNA drugs that have overcome these challenges in humans, focusing on siRNA to treat liver disease and mRNA to vaccinate against COVID, are discussed. Finally, research centered on improving drug delivery to new tissues is highlighted, including the development of high-throughput in vivo nanoparticle DNA barcoding assays capable of testing over 100 distinct nanoparticles in a single animal.
Author Notes
Keywords
Research Categories
  • Engineering, Biomedical

Tools

Relations

In Collection:

Items